Free Trial

Apellis Pharmaceuticals (APLS) ESG Score & Sustainability Data

→ Move Your Money Before May 22 (From Stansberry Research) (Ad)
Free APLS Stock Alerts
$49.86
+1.93 (+4.03%)
(As of 05:27 PM ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability

Key ESG Takeaways for Apellis Pharmaceuticals

The key takeaways are AI-generated and highlight the main contributors behind the net impact scores of Apellis Pharmaceuticals. The insights are based on millions of scientific articles, along with the company-specific product and service portfolio.
  • Apellis Pharmaceuticals seems to create the most significant positive value in categories , , and . The largest positive contribution comes from its impact, which is mostly driven by its Clinical research services for deficiency diseases, Pegcetacoplan, and Clinical research services for genetic diseases products.
  • Apellis Pharmaceuticals uses resources or causes negative impacts mostly in categories , , and . The negative contribution in the impact category seems to be driven mostly by its Pegcetacoplan, Clinical research services for genetic diseases, and Clinical research services for deficiency diseases products.
  • To improve its net impact, a company can either grow its positive impacts, or reduce its negative impacts. For example, by doubling its Preclinical research services for physical health business, Apellis Pharmaceuticals would improve its net impact ratio by 2 percentage points.

APLS Impact Ratio

Net impact ratio represents the net impact of a company. It is defined as the (positive impacts - negative impacts) / positive impacts. The maximum value for net impact ratio is 100%, representing a theoretical company with no negative impacts. The minimum value is -∞. Net scores depend on the value sets that determine the importance of different impact categories.
+67.3%
The default value set, where each category is given the same weight.

Value Sets Value sets can be used to assess how different stakeholder values or emphasis on certain values might affect the net impact ratio.

Millennials
Value set of millennials (b. 1980 - 1999), based on Upright's annual Impact at Work survey.
+72.2%
Most Wanted Workforce
Value set of the most wanted workforce, based on Upright's annual Impact at Work survey.
+60.5%
Society First
Value set that emphasizes society impacts over other impacts.
+28.1%
Knowledge First
Value set that emphasizes knowledge impacts over other impacts.
+84.1%
Health First
Value set that emphasizes health impacts over other impacts.
+81.0%

Apellis Pharmaceuticals ESG Score + Net Impact Profile

ImpactNegativeScorePositive
+1.45
+1.45
+1.71
+1.71
+0.04
+0.04
-0.02
-0.02
+0.00
-0.00
+0.09
+0.09
+0.00
+0.00
+2.85
+2.85
-0.00
+0.00
+0.00
-1.98
-1.98
-0.71
+4.75
+5.46
-0.05
+0.40
+0.45
0.00
+0.00
-0.00
+0.01
+0.01
-0.00
+0.32
+0.33
-0.71
-0.71
+0.00
-0.14
-0.14
+0.00
-0.02
-0.02
+0.00
-0.02
-0.02
+0.00
-0.39
-0.39
+0.00

Upright Model Version 0.6.0
ESG Data Last Updated: October 12, 2022

Ad Stansberry Research
Move Your Money Before May 1
Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens?
Click here to get the full story before May 1. 

About Upright's Net Impact Model

Upright Model

Upright's Net Impact Data quantifies the holistic value creation and impact of companies. It details both the negative and positive impacts a company has on the environment, health of people, society and knowledge, and forms a net sum of these costs and gains based on the economic costs of each impact category. The data is produced by Upright's Net Impact model, which is a mathematical model of the economy that produces continuously updated estimates of the net impact of companies by means of an information integration algorithm. The data is primarily sourced from the CORE open access database, which contains over 200 million scientific papers. Other sources of data include open databases published by the World Bank, IMF, WHO, OECD, IPCC, CDC and USDA.

Apellis Pharmaceuticals ESG Score - Frequently Asked Questions

How is Apellis Pharmaceuticals doing in terms of sustainability?

According to The Upright Project, which measures holistic value creation and impact of companies, Apellis Pharmaceuticals has a net impact ratio of 67.3%, indicating an overall positive sustainability impact. Apellis Pharmaceuticals seems to create the most significant positive value in the categories of Physical diseases, Creating knowledge, and Taxes. Apellis Pharmaceuticals uses resources or causes negative impacts mostly in the categories of Scarce human capital, GHG emissions, and Physical diseases. Learn more on the sustainability of Apellis Pharmaceuticals.


More ESG Stocks and Research Tools

Related Companies:
Stock Lists:
Sustainability Tools:
This page (NASDAQ:APLS) was last updated on 4/26/2024 by MarketBeat.com Staff

From Our Partners
Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share
Colonial Metals
These AI trades triggered this morning (545% return)
Prosper Trading Academy
Exposed: 10 CENT Crypto to Explode April 20th?
True Market Insiders
He Is Giving Away Bitcoin
Crypto Swap Profits
The A.I. story nobody is telling you (Read ASAP)
TradeSmith
Man Who Predicted 2008: “This Will be Worse.”
Altimetry
Fed launches fourth dollar overhaul
Stansberry Research
Biden out June 13; Kamala won’t replace him?
Paradigm Press